- HOPE shares currently owned by NRXP with planned share
dividend to existing NRXP shareholders
- HOPE has now completed initial manufacture of Ketamine for
IV infusion and plans to file FDA New Drug Application for
treatment of acute suicidality upon demonstration of 2-year
shelf stability (expected Q2 2024)
- HOPE plans to file patient-level data from two
well-controlled clinical trials comparing ketamine to placebo in
patients with acute suicidality and depression, which demonstrated
a statistically significant benefit (P<.001)
- HOPE plans to initiate a 506(c) pre-IPO offering of pre-IPO
shares for qualified investors that is structured to potentially
yield both capital appreciation and a royalty on sales of
ketamine
RADNOR, Pa., Feb. 20, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of
NRx Pharmaceuticals, will present a corporate overview at the BIO
CEO & Investor Conference, which is scheduled to take place
February 26-27, 2024, at the Marriott Marquis in New York City.
Presenting with him will be Matthew Duffy, the newly-appointed
co-CEO of HOPE Therapeutics.
Concurrent with the presentation, NRx plans to file a proxy
statement, subject to board approval, for Nasdaq:NRXP shareholders
outlining the share structure and seeking a shareholder advisory
vote to support the planned share dividend for HOPE Therapeutics.
The Company has received consistent advice from public shareholders
that the planned share dividend and royalty coupon be distributed
only to shareholders and warrant-holders who execute a covenant not
to participate in short sales of the Company's stock.
"Subsequent to our initial announcement of HOPE Therapeutics in
December 2023, we have focused on
establishing HOPE's basic corporate and board structure, securing
our manufacturing partnerships and manufacturing initial
productions batches of ketamine, establishing nationwide
distribution, pharmacovigilance, and medical liaison partnerships,
and initiating plans to pair ketamine therapy with a novel digital
therapeutic that has potential to reinforce the effect of
NMDA-targeted drug therapy in reducing suicidal ideation and
depression," said Dr. Javitt. "We thank our investors for their
support and look forward to updating the public on our progress
towards building a lifesaving therapy."
Presentation Date: Monday, February 26th, 2024
Time: 2:30 PM ET
Location: The Royale Room, Marriott Marquis, New York City
Registration: https://bcic.bio.org/registration
SIMULCAST: BIZTV
Information will be available on the NRx website at
https://ir.nrxpharma.com/events prior to the conference.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain, and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen and Lotus around the
development and marketing of NRX-101 for the treatment of suicidal
bipolar depression. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for HTX-100 (IV ketamine), through Hope Therapeutics,
in the treatment of suicidal depression, based on results of
well-controlled clinical trials conducted under the auspices of the
US National Institutes of Health and newly obtained data from
French health authorities, licensed under a data sharing agreement.
NRx was awarded Fast Track Designation for development of ketamine
(NRX-100) by the US FDA as part of a protocol to treat patients
with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
wholly-owned subsidiary of NRX Pharmaceuticals focused on
development and marketing of an FDA-approved form of intravenous
ketamine for the treatment of acute suicidality and depression
together with a digital therapeutic-enabled platform designed to
augment and preserve the clinical benefit of NMDA-targeted drug
therapy.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-to-launch-hope-therapeutics-inc-at-the-bio-ceo--investor-conference-2024-302065827.html
SOURCE NRx Pharmaceuticals